Polish companies have spent years operating in an environment shaped by economic volatility, regulatory change, labour shortages, geopolitical risks and repeated disruptions to supply chains. While these conditions have made doing business more difficult, they may also have created an important competitive advantage: a generation of executives accustomed to making fast decisions, managing uncertainty and continuously adapting their organisations to changing conditions.
The number of foreign nationals working in Poland reached a record 1.13 million at the end of February 2026, rising 7.1% year-on-year, according to Statistics Poland (GUS). Ukrainian citizens remained by far the largest group, while foreign workers continued to play a particularly important role in manufacturing, logistics, construction and business support services.
Polish companies have spent years operating in an environment shaped by economic volatility, regulatory change, labour shortages, geopolitical risks and repeated disruptions to supply chains. While these conditions have made doing business more difficult, they may also have created an important competitive advantage: a generation of executives accustomed to making fast decisions, managing uncertainty and continuously adapting their organisations to changing conditions.
The Edison system, developed by US-based HistoSonics and using histotripsy technology for the non-invasive treatment of liver tumours, has received CE certification authorising its...
Synektik, a listed provider of advanced medical technologies and producer of radiopharmaceuticals, closed the first half of its 2025 financial year with the highest...
Synektik is beginning operational activity on the Ukrainian market. A local company and team have already been established in Ukraine to handle sales and...
On March 27, 2026, the registry court entered into the National Court Register (KRS) the increase in Syn2bio’s share capital related to the issuance...
The Extraordinary General Meeting of Synektik has unanimously approved the division of the listed company, under which its business related to research on a...
Syn2bio – the newly established company to which Synektik plans to transfer its activities related to research on its cardiotracer and the future commercialization...